Latest Insider Transactions at Theravance Biopharma, Inc. (TBPH)
This section provides a real-time view of insider transactions for Theravance Biopharma, Inc. (TBPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Theravance Biopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Theravance Biopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2023
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,114
-2.64%
|
$64,026
$9.7 P/Share
|
|
Aug 20
2023
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-0.97%
|
$142,236
$9.7 P/Share
|
|
Aug 20
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
10,460
-2.96%
|
$94,140
$9.7 P/Share
|
|
Aug 20
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
10,461
-2.99%
|
$94,149
$9.7 P/Share
|
|
Aug 11
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,322
-0.66%
|
$20,898
$9.99 P/Share
|
|
Jul 14
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,322
-0.66%
|
$20,898
$9.84 P/Share
|
|
Jun 14
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,322
-0.65%
|
$23,220
$10.69 P/Share
|
|
Jun 08
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
1,790
-0.5%
|
$19,690
$11.13 P/Share
|
|
May 20
2023
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,744
-3.15%
|
$96,184
$11.21 P/Share
|
|
May 20
2023
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-0.96%
|
$173,844
$11.21 P/Share
|
|
May 20
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
5,567
-1.55%
|
$61,237
$11.21 P/Share
|
|
May 20
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
10,460
-2.85%
|
$115,060
$11.21 P/Share
|
|
May 20
2023
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
11,469
-3.75%
|
$126,159
$11.21 P/Share
|
|
May 15
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,322
-0.63%
|
$25,542
$11.26 P/Share
|
|
May 02
2023
|
Donal O'Connor |
BUY
Grant, award, or other acquisition
|
Direct |
9,132
+14.69%
|
-
|
|
May 02
2023
|
Deepika Pakianathan |
BUY
Grant, award, or other acquisition
|
Direct |
9,132
+19.85%
|
-
|
|
May 02
2023
|
Burton G Malkiel |
BUY
Grant, award, or other acquisition
|
Direct |
9,132
+8.32%
|
-
|
|
May 02
2023
|
Dean J Mitchell |
BUY
Grant, award, or other acquisition
|
Direct |
9,132
+11.54%
|
-
|
|
May 02
2023
|
Eran Broshy |
BUY
Grant, award, or other acquisition
|
Direct |
9,132
+11.54%
|
-
|
|
May 02
2023
|
Susannah Gray |
BUY
Grant, award, or other acquisition
|
Direct |
9,132
+30.36%
|
-
|
|
May 02
2023
|
Alsup Laurie Smaldone |
BUY
Grant, award, or other acquisition
|
Direct |
9,132
+14.51%
|
-
|
|
Apr 14
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,323
-0.62%
|
$25,553
$11.88 P/Share
|
|
Mar 14
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,323
-0.62%
|
$23,230
$10.32 P/Share
|
|
Mar 09
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
4,000
-1.1%
|
$40,000
$10.2 P/Share
|
|
Mar 06
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,323
-0.62%
|
$23,230
$10.05 P/Share
|
|
Mar 01
2023
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
330,000
+16.72%
|
-
|
|
Mar 01
2023
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+19.74%
|
-
|
|
Mar 01
2023
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+22.36%
|
-
|
|
Mar 01
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+17.08%
|
-
|
|
Mar 01
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+16.61%
|
-
|
|
Feb 26
2023
|
Susannah Gray |
BUY
Grant, award, or other acquisition
|
Direct |
11,819
+31.25%
|
-
|
|
Feb 20
2023
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
37,420
-2.77%
|
$374,200
$10.44 P/Share
|
|
Feb 20
2023
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
6,783
-3.32%
|
$67,830
$10.44 P/Share
|
|
Feb 20
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
12,057
-3.85%
|
$120,570
$10.44 P/Share
|
|
Feb 20
2023
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
10,198
-4.25%
|
$101,980
$10.44 P/Share
|
|
Feb 20
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
7,119
-2.4%
|
$71,190
$10.44 P/Share
|
|
Dec 14
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
50,000
-3.57%
|
$550,000
$11.19 P/Share
|
|
Dec 13
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
9,000
-0.64%
|
-
|
|
Dec 01
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,084
-0.66%
|
$20,840
$10.73 P/Share
|
|
Nov 22
2022
|
Donal O'Connor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-18.56%
|
$100,000
$10.5 P/Share
|
|
Nov 20
2022
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
23,268
-7.28%
|
$232,680
$10.85 P/Share
|
|
Nov 20
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
27,350
-7.97%
|
$273,500
$10.85 P/Share
|
|
Nov 20
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
25,057
-6.11%
|
$250,570
$10.85 P/Share
|
|
Nov 20
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-1.11%
|
$158,040
$10.85 P/Share
|
|
Nov 18
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
65,000
-13.69%
|
$715,000
$11.02 P/Share
|
|
Nov 16
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
2,800
-0.81%
|
$30,800
$11.2 P/Share
|
|
Sep 16
2022
|
Glaxosmithkline PLC |
SELL
Other acquisition or disposition
|
Indirect |
9,644,807
-100.0%
|
$86,803,263
$9.75 P/Share
|
|
Aug 19
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-1.1%
|
$142,236
$9.34 P/Share
|
|
Aug 19
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
25,676
-5.14%
|
$231,084
$9.34 P/Share
|
|
Aug 19
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
18,991
-5.21%
|
$170,919
$9.34 P/Share
|